Practical Cure Projects in Human Clinical Trials 2012 Update
December 17, 2012
This report reveals that of the 329 type 1 human clinical trials, there are just six with the potential to deliver a Practical Cure. While one project was added to this list since 2011, a greater focus on Practical Cure work will push more projects into human clinical trials. Click here to read more.
What can donors do to drive practical cure development?
November 30, 2012
This report discusses the actions that donors can take to increase funding for Practical Cure research. This area of research receives little attention from the major diabetes non-profits; only three cents of every cure research dollar are applied to Practical Cure research. Click here to read more.
State of the Cure 2012
November 19, 2012
This report is the inaugural publication of what will be a yearly update series. It summarizes the findings from many of our reports to create a comprehensive picture of factors that impact cure research and how we as donors can impact progress. The report shows that there is much more that affects cure development than simply research in a laboratory. How is research chosen? How is money raised? How are donor contributions utilized? What scientific milestones have been accomplished? The report addresses all of these topics. Click here to read more.
Are Fundraising Event Proceeds Used for the Purpose for Which the Money Was Solicited?
October 25, 2012
This report analyzes the cure message that diabetes non-profits use to solicit contributions at fundraising events. The JDCA reviewed over 400 fundraising events that the major diabetes non-profits organized in the United States in 2012. Click here to read more.
Type 1 Research Funding Infrastructure in the U.S.
September 14, 2012
This report provides an introduction to the infrastructure that supports type 1 diabetes research in the United States. With the donors’ interest in mind, we follow the money trail from its source to the laboratory. Click here to read more.
What is the role of the board at the non-profits?
August 1, 2012
This report, the fifth in our corporate governance series, examines the role of the non-profits’ governing Board and its effectiveness in the pursuit of a type 1 cure. Click here to read more.
How do the major type 1 non-profits rate on corporate governance issues?
July 29, 2012
This is the third report in an ongoing series of analyses on corporate governance among the four non-profits in the
JDCA’s coverage universe. This report rates the non-profits’ proficiency in four key corporate governance areas: financial data, strategic direction, cure progress, and enterprise governance. Click here to read more.
Are Non-profit executive financially incentivized to ACHIEVE a type 1 cure?
July 18, 2012
Execuve compensaon is a crical element of corporate governance. This report, the fourth in our corporate governance
series, examines the degree to which financial incentives are a factor in the development of a cure for type 1. Click here to read more.
Is type 1 cure research focused enough?
May 1, 2012
This report examines the organizations’ approach to funding type 1 cure research and proposes an alternative strategy that could accelerate the development of a type 1 cure. Click here to read more.
Shrinking Funding Of Type 1 Cure Research By the Four Major Non-Profits
April 5, 2012
This report slightly longer term view and analyze the trend in funding for type 1 cure research in comparison to the organizations’ funding of other research activities over the past four years. Click here to read more.
The Disconnect Between the Cure Message Used to Solicit Donations and the Allocation of Those Donations
March 22, 2012
In this report we analyze the primary messages the major diabetes charities use to solicit donations and examine the relationship between those messages and the non-cure activities that donations fund. Click here to read more.
Improved Corporate Governance Begins with Frequency, Timeliness, and Notification
march 16, 2012
We believe that a lack of transparency exists at not-for-profit (NFP) foundations and that the four diabetes NFPs that we actively follow would benefit from providing reports that follow SEC standards. Click here to read more.
Donor intentions and cure myths revealed
March 15, 2012
Survey data reveals that myths surrounding a cure are widespread and contribute to donor disillusionment and frustration. Click here to read more.
Utilizing corporate governance to align agendas
March 9, 2013
The JDCA feels that existing and potential NFP stakeholders would be be+er served by improved communication frequency, timeliness, and disclosure requirements that more closely mirror the SEC guidelines used by Public Companies. Click here to read more.
Review of Expense categories at the major type 1 non-profits
March 8, 2012
This report updates and analyzes the charities’ spending in the major expense categories based on their most recent financial statements. Click here to read more.
Prevention Does not Lead to a cure
February 23, 2012
The JDCA believes there are misconceptions relating to prevention research and its relationship to the development of a cure. This report addresses those misconceptions and details why pursuit of prevention research could be detrimental to efforts to cure individuals living with type 1. Click here to read more.
Type 1 Treatment Innovations Have Not Derived from Non-Profits
February 9, 2012
This report delineates the reasons why the pursuit of type 1 treatment objectives is best accomplished by commercial enterprises rather than the non-profits. Click here to read more.
Type 1 Human Clinical Trial Landscape
January 19, 2012
This is the last in a series of three reports that examines the type 1 diabetes (type 1) clinical trial landscape. In this report, we broadly analyze the type 1 trial universe, the focus of research attention and the implications for the development of a type 1 Practical Cure. Click here to read more.